Compare · CRBP vs NVO
CRBP vs NVO
Side-by-side comparison of Corbus Pharmaceuticals Holdings Inc. (CRBP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRBP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 1371.5x CRBP ($136.7M).
- Over the past year, CRBP is down 12.9% and NVO is down 41.7% - CRBP leads by 28.8 points.
- CRBP has been more active in the news (21 items in the past 4 weeks vs 11 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for CRBP).
- Company
- Corbus Pharmaceuticals Holdings Inc.
- Novo Nordisk A/S
- Price
- $7.38-2.32%
- $42.01-2.10%
- Market cap
- $136.7M
- $187.53B
- 1M return
- -29.88%
- -5.38%
- 1Y return
- -12.87%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 21
- 11
- Recent ratings
- 10
- 25
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CRBP
- Chief Business Officer Saxena Nishant C bought $101,218 worth of shares (13,500 units at $7.50), increasing direct ownership by 22% to 75,300 units (SEC Form 4)
- SEC Form S-8 filed by Corbus Pharmaceuticals Holdings Inc.
- Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
- Chief Business Officer Saxena Nishant C was granted 58,300 shares, increasing direct ownership by 1,666% to 61,800 units (SEC Form 4)
- New insider Saxena Nishant C claimed ownership of 3,500 shares (SEC Form 3)
- Director Kung Winston was granted 3,800 shares, increasing direct ownership by 37% to 14,166 units (SEC Form 4)
- Director Jacques Rachelle Suzanne was granted 3,800 shares, increasing direct ownership by 50% to 11,383 units (SEC Form 4)
- Director Jenkins John Kenneth was granted 3,800 shares, increasing direct ownership by 79% to 8,633 units (SEC Form 4)
- Director Ben Yong was granted 3,800 shares, increasing direct ownership by 50% to 11,383 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates